CMC Biologics and Harpoon Therapeutics have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of various human cancers.
Harpoon Therapeutics’ TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules contain three binding domains: one domain binds a specific tumor target, the second domain binds to human serum albumin, and the third domain binds to T-cells.
“With great strides being taken daily in the discovery and development of new oncology treatments, we’re delighted to be working with Harpoon Therapeutics on these exciting new TriTAC molecules, enabling CMC Biologics to participate in the roll-out of transformative new treatments with the potential to significantly impact patient lives,” said Gustavo Mahler, PhD, chief executive officer and president of CMC Biologics.
Harpoon’s first clinical candidate, HPN424, a prostate-specific membrane antigen, is in development for the treatment of metastatic prostate cancer and expected to enter Phase 1 clinical trials in 2018.